Description
Pear Therapeutics is a commercial-stage healthcare company.
The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. Its reset product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for treatment of opioid use disorder (OUD) in combination with buprenorphine.
Its Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas such as gastrointestinal (GI), oncology, and cardiovascular. It focuses on psychiatric and neurologic conditions, which supports its strategy to commercialize its own products.
